Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model by Manoranjenni Chetty et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 05 January 2015
doi: 10.3389/fimmu.2014.00670
Prediction of the pharmacokinetics, pharmacodynamics,
and efficacy of a monoclonal antibody, using a
physiologically based pharmacokinetic FcRn model
Manoranjenni Chetty 1*, Linzhong Li 1, Rachel Rose1, Krishna Machavaram1, Masoud Jamei 1,
Amin Rostami-Hodjegan1,2 and Iain Gardner 1
1 Simcyp Limited (a Certara Company), Sheffield, UK
2 Manchester Pharmacy School, Manchester University, Manchester, UK
Edited by:
Jan Terje Andersen, Oslo University
Hospital, Norway
Reviewed by:
Dan Frenkel, Tel Aviv University, Israel
Daniel Olive, INSERM UMR 891
Institut Paoli Calmettes, France
*Correspondence:
Manoranjenni Chetty , Simcyp Limited
(a Certara Company), Blades
Enterprise Centre, John Street,
Sheffield S2 4SU, UK
e-mail: m.chetty@simcyp.com
Although advantages of physiologically based pharmacokinetic models (PBPK) are now
well established, PBPK models that are linked to pharmacodynamic (PD) models to predict
pharmacokinetics (PK), PD, and efficacy of monoclonal antibodies (mAbs) in humans are
uncommon.The aim of this study was to develop a PD model that could be linked to a phys-
iologically based mechanistic FcRn model to predict PK, PD, and efficacy of efalizumab.
The mechanistic FcRn model for mAbs with target-mediated drug disposition within the
Simcyp population-based simulator was used to simulate the pharmacokinetic profiles for
three different single doses and two multiple doses of efalizumab administered to vir-
tual Caucasian healthy volunteers. The elimination of efalizumab was modeled with both
a target-mediated component (specific) and catabolism in the endosome (non-specific).
This model accounted for the binding between neonatal Fc receptor (FcRn) and efalizumab
(protective against elimination) and for changes in CD11a target concentration. An inte-
grated response model was then developed to predict the changes in mean Psoriasis Area
and Severity Index (PASI) scores that were measured in a clinical study as an efficacy
marker for efalizumab treatment. PASI scores were approximated as continuous and fol-
lowing a first-order asymptotic progression model. The reported steady state asymptote
(Y ss) and baseline score [Y (0)] was applied and parameter estimation was used to deter-
mine the half-life of progression (T p) of psoriasis. Results suggested that simulations using
this model were able to recover the changes in PASI scores (indicating efficacy) observed
during clinical studies. Simulations of both single dose and multiple doses of efalizumab
concentration-time profiles as well as suppression of CD11a concentrations recovered clin-
ical data reasonably well. It can be concluded that the developed PBPK FcRn model linked
to a PD model adequately predicted PK, PD, and efficacy of efalizumab.
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INTRODUCTION
Binding to the neonatal Fc receptor (FcRn) as well as therapeu-
tic targets in vivo have a significant influence on the disposition
of a monoclonal antibody (mAb). Physiologically based pharma-
cokinetic (PBPK) models describing some of these processes in
the disposition of mAbs in pre-clinical species and humans, have
recently been published (1–6). PBPK models are mechanistic and
are regarded as a more realistic representation of drug disposition
in vivo. However, the ultimate interest in mAbs is their thera-
peutic potential and the majority of current PBPK models have
not advanced to include prediction of response to mAbs. A PBPK
model linked to a pharmacodynamics model (PD) will offer the
advantage of predicting both the PK variability and the response
to a mAb. In addition, input to the PD model can be done from
a tissue interstitial compartment and not just from plasma, which
is important when modeling membrane bound receptors.
The PKs of mAbs are complex and have been reviewed (7–
11). Key aspects of PBPK models for mAbs represent the tissue
physiology and quantitation of the distribution, metabolism, and
elimination of mAbs. These include characterization of the tis-
sue structure to account for the vascular space, interstitial space
(where the drug target can be located), and the endosomal space
(where non-specific catabolism of the mAb may occur); distribu-
tion of mAbs by diffusion and convection (extravasation); binding
of immunoglobulin G (IgG) to FcRn to account for protection of
mAbs from degradation, as well as specific high-affinity catabo-
lism (receptor-mediated endocytosis) due to binding of the mAb
to a specific target, i.e., target-mediated drug disposition (TMDD),
where relevant. Binding of the mAb to the specific target may also
produce the PD effects and pharmacological response to the mAb,
which varies with dynamic changes in the availability of the free
target sites. The latter feature of mAbs can be characterized using
PBPK models linked to PD models.
Psoriasis is a chronic inflammatory skin disorder with a prolif-
eration of keratinocytes and accumulation of activated T cells in
skin lesions. This incurable autoimmune disease is characterized
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by lesions in the epidermis and dermis and is mediated by T
lymphocytes. Leukocyte-function associated-antigen type 1 (LFA-
1) is a T lymphocyte adhesion molecule, which plays a crucial
role in the pathogenesis of psoriasis. Efalizumab is a recombi-
nant humanized IgG1 mAb that inhibits T-cell adhesive inter-
actions by binding to CD11a, which is the alpha subunit of
LFA-1. Blockade of the CD11a target results in the interruption
of the immunological cascade responsible for psoriatic plaque
formation (12, 13).
Response of psoriasis to a therapeutic intervention can be
assessed using the Psoriasis Area and Severity Index (PASI) score.
Several clinical studies that have evaluated the PK and response
to different doses of efalizumab in psoriasis have been published
(12, 14–18), providing adequate clinical data for the development
and verification of a PBPK model linked to a PD model. Thus,
although efalizumab is no longer used therapeutically (due to tox-
icity), it is used to illustrate the application of the PBPK/PD model
in this study.
The aim of this study was to develop a PD model that is linked
to the Mechanistic FcRn Model for mAbs within the Simcyp Pop-
ulation Based Simulator to simulate the efficacy of efalizumab in
patients with plaque psoriasis.
MATERIALS AND METHODS
PBPK MODEL TO CHARACTERIZE mAb PK AND TMDD
The Simcyp population based simulator (Version 13 R1) was used
to construct a PBPK model with TMDD for efalizumab, in a vir-
tual north European Caucasian population. Parameters used in
the efalizumab compound file are listed in Table 1 (19–21). The
Mechanistic FcRn model, which accounts for disposition of mAbs
in the vascular, endothelial, and interstitial layers within the tissue
compartment, was used (22) (Figure 1). Key features of this model
include:
• Transport of mAbs through pores in the endothelial cells
and lymph vessels by convection (modeled using reflection
coefficients).
Table 1 | Parameter values used for efalizumab in the Simcyp
Simulator.
Parameter Value Reference/comments
MW: molecular weight
of efalizumab
148841 g/mol (19)
K D: equilibrium binding
constant from FcRN
2.96423µM Estimated using linear
regression and the relationship
between half-life and K D as
per Suzuki et al. (21)
CLiv: clearance 0.0227 l/h;
CV%=30
(20)
Molecular weight of
target CD11a
150000 Da (20)
K deg: degradation rate
of the target ieCD11a
0.0185 1/h;
CV%=10
(4)
K m: rate constant for
receptor complex
internalization and
degradation
0.000573µM (20)
K int: internalization rate
constant for the complex
0.1 l/h (18)
Rmax: CD11a abundance 0.01µM Estimated
K syn: rate of synthesis
of target
0.000185µM/h K syn=Rmax*K deg
FIGURE 1 | Model structure of the physiologically based Mechanistic
FcRN model for mAbs coupled with a Michaelis–Menten based
target-mediated drug disposition (MMTMDD) model. Q – plasma flow
rate, L – lymph flow rate, K up – endothelia uptake rate, σv – vascular
reflection coefficient, σi – lymphatic reflection coefficient, K rc – rate of
recycling of bound IgG, FR – recycling fraction of FcRn-bound IgG, δ – ratio
of uptake rates in luminal and abluminal sides, K D – equilibrium
dissociation constant for IgG and FcRn binding, CLcat – intrinsic clearance
of IgG, [R]T – total target concentration, k syn – first-order synthesis rate
constant of target, k deg – zero-order degradation rate of target,
k int – internalization rate constant of complex, k on – association rate
constant of drug and target, k off – dissociation rate constant of drug–target
complex. Superscripts “en” and “ex” represent endogenous and
exogenous IgGs, respectively.
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• Competitive binding of exogenous (efalizumab) and endoge-
nous IgG to FcRn in the endothelial space. FcRn-bound IgG is
transported to either the vascular (recycling) or interstitial layers
(transcytosis).
• Catabolism of free IgG (unbound to FcRn) in the lysosomes of
the endothelial space.
The PD effects of efalizumab on CD11a free concentrations
as well as the catabolism of efalizumab resulting from binding to
CD11a was quantified using a Michaelis–Menten (MM) approx-
imation of the TMDD model as described by Gibiansky and
coworkers (23) (Figure 1), which accounted for the following:
• Binding of efalizumab to free CD11a characterized by kon.
• Dissociation of the efalizumab–CD11a complex (koff).
• Internalization or degradation of the complex (k int).
• Saturation of CD11a binding sites.
• Changes in CD11a concentration due to synthesis (K syn) and
degradation (K deg).
• K m (rate constant for receptor complex internalization and
degradation) is used in the MM model and incorporates kon,
koff , and k int.
This PBPK model with TMDD for efalizumab was verified by
comparison of the predicted concentration-time outputs for single
and multiple doses with observations from the following clinical
trials:
1 mg/kg – Bauer et al. (12);
3 mg/kg – Bauer et al. (12) and Ng et al. (18);
10 mg/kg – Bauer et al. (12);
multiple dosing: 0.3 mg/kg/week for week 1, 0.4 mg/kg/week for
week 2;
0.6 mg/kg/week for week 3 and 1 mg/kg/week for the next
4 weeks – Gottlieb;
1 mg/kg/week – Ng et al. (18).
Reported mean data from these studies were obtained by
digitization (Digidata®).
Relevant predicted and observed pharmacokinetic parameters
were also compared.
To demonstrate the relevance of TMDD on the disposition
of mAbs, PK of the three single doses were compared with and
without TMDD.
Free CD11a levels were used to evaluate the PD effects of efal-
izumab. Predicted changes in CD11a concentrations as a% of
baseline concentrations (at time 0 h) were compared with those
observed clinically (14).
PBPK/PD MODEL TO SIMULATE mAb EFFICACY
An integrated response model was constructed to predict the
changes in mean PASI scores that were measured in a clinical
study (14), as an efficacy marker for efalizumab treatment. This
was based on the following mathematical relationship, where Y (t )
is the rate of progression of the disease, Y ss is the steady state
asymptote, and T p is the half-life of progression (24):
Y (t ) = Yss + (Y (0)− Yss)e−
ln 2
Tp × t
Psoriasis Area and Severity Index scores were approximated as
continuous and following the first-order asymptotic progression
model with baseline score (Y 0) modulated in proportion to con-
centration of bound CD11a. Both the baseline PASI score (Y 0)
and the steady state asymptote (Y ss) were obtained from a clinical
study (14). The half-life of progression of the psoriasis (T p) in this
model was obtained by parameter estimation.
The study design used by Gottlieb and coworkers (14) was
used for initial model construction. The model corresponded to
their study arm in which patients with moderate to severe psori-
asis (mean baseline PASI score of 24.8 – CV% 10.8) were given
an escalating dosage regimen of efalizumab (0.3 mg/kg in week 1;
0.4 mg/kg in week 2; 0.6 mg/kg in week 3; and 1 mg/kg/week for
the following 4 weeks) by infusion (1 h). PASI scores were assessed
weekly and a mean score of approximately 14.8 (CV% 22) was
observed in the last three consecutive weeks. This value was used
as the Y ss in the model. The constructed model was tested for its
ability to recover the changes in PASI scores observed clinically by
visual comparisons of the mean response–time curves.
The applicability of this model to predict mAb efficacy in
other patient cohorts was then evaluated. The mean baseline was
changed to 19, corresponding to that in the study by Gordon et al.
(16). Since a 1 mg/kg/week given by iv infusion usually produces
a change in PASI score from baseline of about 45–50%, Y ss was
given a value of 9.5. The predicted response over time was then
compared with that observed clinically. The simulation was con-
sidered to be adequate when the observed data points were within
the predicted 5th and 95th centile.
SIMULATIONS
Simulations were conducted with five trials using virtual north
European Caucasian Healthy Volunteers. For replication of clin-
ical observations, simulations were based on trial designs that
were as close as possible to the clinical study design. Predictive
studies used 5 trials with 100 virtual north European Caucasian
Healthy Volunteers each, aged between 25 and 50 years, with an
equal proportion of males and females. A visual comparison was
done between predicted and observed concentration–time profiles
and response–time profiles to verify suitability of the models. The
simulation was considered to be adequate when the observed data
points were within the predicted 5th and 95th centile.
RESULTS
PK OF SINGLE AND MULTIPLE DOSES OF EFALIZUMAB
Application of the mechanistic FcRn model with TMDD predicted
concentration–time profiles for efalizumab 1, 3, and 10 mg/kg ade-
quately, as can be seen in Figure 2A. Corresponding predicted
versus observed clearance values are shown in Table 2 and indicate
that the model was able to predict PK adequately.
Application of the model for prediction of PK using multiple
dosing also recovered clinical data from Gottlieb et al. (15) and Ng
et al. (18) adequately (Figure 2C).
TMDD EFFECTS ON mAb DISPOSITION
Differences in the PK of efalizumab, in the absence of binding
to CD11a, are shown in Figure 2B. The lower clearance val-
ues obtained in the absence of TMDD are shown in Table 2.
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FIGURE 2 | Predicted concentration–time profiles for three
different single doses of efalizumab, comparing the
concentration–time profiles withTMDD in the model [graphs
(A): (A1–A3)] and withoutTMDD [graphs (B): (B1–B3)]. The
prediction is improved by TMDD since more of the clinically observed
values lie within the 5–95 percentiles of the prediction (broken lines).
Predicted concentration–time profile for multiple dosing with TMDD is
shown in (C).
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Table 2 | Predicted and observed CL.
Dose (mg/kg) Observed CL
(ml/day/kg);
Mean (range)
Predicted CL
(ml/day/kg);
Mean (range)
Predicted CL
(ml/day/kg);
Mean (range)
WithTMDD WithoutTMDD
1 15.6a (10.6–20.6) 11.65 (10.3–11.8) 9.23 (8.2–9.5)
3 10.7a (7.1–13.3) 10.09 (8.9–10.2) 9.01 (7.9–9.1)
10 6.64a,b 9.3 (8.3–9.5) 9.01 (7.9–9.07)
aRef. (12).
bResult from one subject.
FIGURE 3 | Predicted and observed changes in CD11a concentration
expressed as a % of baseline.
Results suggest that TMDD is more important for lower drug
concentrations.
PREDICTION OF FREE CD11a CONCENTRATIONS AS A% OF THE
BASELINE DURING EFALIZUMAB TREATMENT
The predicted suppression of CD11a concentrations that were sus-
tained over the treatment period are shown in Figure 3. Mean
predicted CD11a% were marginally lower than those observed in
the study by Gottlieb et al. (15).
PBPK LINKED PD MODEL
A fitted T p parameter value of 397 h was obtained using para-
meter estimation module of the Simulator and the clinical data
by Gottlieb et al. (15) Visual predictive checks suggested that the
resulting PBPK/PD model was reasonably successful at recovering
the changes in PASI scores over time as observed by Gottlieb et al.
(15) using escalating dosage (Figure 4). This developed model was
then used successfully to predict response observed clinically by
Gordon et al. (16) for a dose of 1 mg/kg (Figure 4) by using just
the mean baseline score of the patients in the latter clinical study.
DISCUSSION
A PBPK model with a linked PD model that successfully predicted
the pharmacokinetics, immunobiologic, and efficacy of a mAb,
was developed in this study. Although a limited number of PBPK
FIGURE 4 | Predicted changes in PASI scores during the treatment
period.
models that predict mAb PK have been published, PBPK models
that predict pharmacokinetics as well as PD and efficacy in humans
are uncommon.
The concentration–time profiles of efalizumab in Figure 2
suggest that this model predicts the PK of single as well as multi-
ple doses of efalizumab reasonably well. Visual inspection of the
concentration–time profiles for 1, 3, and 10 mg/kg suggested a rea-
sonable recovery of the clinical data, with all data points within
the 95th and 5th percentile. A comparison of the predicted and
observed clearance values (Table 2) show that the predicted val-
ues for 1 and 3 mg/kg are within the observed ranges. Predicted
clearance for 10 mg/kg was higher than the clearance reported
by Bauer et al. (12), but only one patient received that dose in
the Bauer study. The concentration–time profile following mul-
tiple dosing was also favorable predicted as seen in Figure 2C.
Gottlieb and coworkers (14) measured peak (Cmax) and trough
(Cmin) concentrations following a dosing regimen that escalated
from 0.3 mg/kg in week 1 to 1 mg/kg in week 4. The simulation in
this study used a similar dosing regimen and was able to recover
the observed data adequately. Ng and coworkers (18) reported
concentrations following a dose of 1 mg/kg/week. In general, the
model was successful at predicting the disposition of efalizumab.
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Efalizumab clearance was influenced by TMDD. Binding to
CD11a produced the desired therapeutic effects of efalizumab but
also lead to internalization of the drug–target complex and catab-
olism. This was a highly specific clearance process because of the
target specificity and was also saturable, based on free target avail-
ability. The model accounted for changing concentrations of the
target (due to synthesis and degradation). Thus, the mechanistic
FcRn model coupled with the Michaelis–Menten approximation
of the TMDD model (23) adequately predicted the disposition of
efalizumab.
The reduced ability of the model without TMDD to predict
concentration–time profiles for efalizumab (especially at lower
doses – Figure 2B) illustrates the importance of TMDD in the PK
of efalizumab. It is suggested that at higher mAb concentrations,
the target concentrations may be saturated, making the TMDD
pathway less important in clearance.
The binding of mAbs to specific targets for their therapeutic
activity make this therapeutic class attractive to immunologists
and clinicians. Efalizumab, which was indicated for the treat-
ment of psoriasis, is known as an anti-CD11a drug since its binds
to CD11a, a cell surface receptor. Efalizumab binds to CD11a,
which is the α subunit of LFA-1, thereby interrupting the T
lymphocyte-mediated actions and alleviating the symptoms of
psoriasis. Clinical studies have shown a significant downregula-
tion of CD11a concentrations (typically to about 25% of baseline)
(18) during efalizumab administration. A sustained downregula-
tion of CD11a has been accompanied by favorable reductions in
PASI scores. The model in this study predicted the suppression of
the CD11a concentrations (Figure 3). These were marginally lower
than those observed by Gottlieb et al. (15). However, significant
inter-individual variability has been reported for CA11a (18).
The disease progression model used to characterize this chronic
autoimmune disease accounts for the symptomatic relief by efal-
izumab as shown by the improvement in PASI scores. Efalizumab
modulates the baseline PASI score, i.e., Y (0), which corresponds
to symptomatic effect, without having any effect on the half-life
of the disease progression (T p). The model recovered clinically
observed changes in PASI corresponding to efalizumab treatment
reasonably well, as seen in Figure 4. Use of this model to predict
changes in PASI scores over time for other patient groups, as in
the case of the clinical study by Gordon et al. (16), illustrates the
robustness of the model and its potential utility during drug devel-
opment and clinical practice. This study suggests that a PBPK/PD
model that is developed for a mAb may be used to make predic-
tions based on different population groups, disease severity, and
perhaps different dosages and formulations. The model also has
the potential for application to other mAbs in the same therapeutic
class, for comparison of efficacy.
Although reasonably good predictions of PK, PD, and efficacy
were obtained using this PBPK linked PD model, some opportu-
nities may exist for improvement of the model. Firstly, parameter-
ization of the PBPK model is generally problematic because of the
limited data and the general lack of consensus on PBPK models
for mAbs, especially in humans. The variability on the parameters
in the disease progression model may also be a limitation, since
mean data were obtained from published studies and variability
could not be accurately assessed. This model does not account for
anti-CD11a antibodies. While the PD model predicted the PASI
scores over time for the two studies and different doses, application
of this model to other compounds will require some knowledge of
the expected maximum change in PASI score for the compound.
In addition, this model is not designed to simulate placebo effects
of the drug.
Based on the acceptable predictions of efalizumab clearance,
concentration–time profiles, CD11a suppression and simulations
of PASI score changes over the treatment period, it can be con-
cluded that the study was successful in developing a PD model
linked to a mechanistic FcRn PBPK model to predict PK, PD, and
efficacy of mAbs in humans. Similar models can be constructed
for “testing” various “what/if” scenarios during mAb development
and thereby inform the designs of clinical studies. PBPK models
provide the opportunity for simulation of various scenarios that
may not be included in initial clinical trials such as differences in
FcRn abundances, target concentrations, patients of different eth-
nicities, special population groups, as well as mAbs with variable
affinities for FcRn or the target.
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